Evidence map›Paper›PMID 38332742›Full record

ArticleThe Journal of pathology2024

Upcycling HOXB13: enhancing prostate cancer detection with a novel antibody

Anke Augspach, Mark A Rubin

Open access · hybridAbstract readComment
PubMed Publisher
In one paragraph

Article in The Journal of pathology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Anke AugspachDepartment for BioMedical Research, University of Bern, Bern, Switzerland.ORCID 0000-0002-3788-2719
Mark A RubinDepartment for BioMedical Research, University of Bern, Bern, Switzerland.ORCID 0000-0002-8321-9950
University of Bern · CH

Funding

Prostate Cancer Foundation 22CHAL03
6 · The paper itself

Abstract

Prostate cancer is one of the most prevalent and, upon metastasis, deadliest cancers in men. Timely identification is essential for effective treatment. Furthermore, accurate determination of prostatic origin is crucial for personalized therapy once the cancer has spread. However, current prostate cancer screening methods are lacking. A recent article in The Journal of Pathology addresses this issue by utilizing an improved antibody to reevaluate HOXB13 as a lineage marker for prostate cancer. The study's findings support the concept that, despite decreased expression in advanced prostate cancer, HOXB13 remains highly suitable for determining prostatic origin due to its androgen receptor independence, high specificity, and sensitivity. © 2024 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.

Indexed as

Prostatic NeoplasmsBiomarkers, TumorEarly Detection of CancerHomeodomain ProteinsHumansImmunoglobulinsMaleProstateProstate-Specific AntigenBiomarkers, TumorHomeodomain ProteinsHOXB13 protein, humanImmunoglobulinsProstate-Specific Antigenandrogen receptorHOXB13lineage markerneuroendocrine prostate cancerprecision oncologyprostate cancer

Identifiers

PMID38332742
OpenAlexW4391685388

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.